Cited by 267Multiple Myeloma Research and TreatmentsEpigenetics and DNA MethylationAcute Myeloid Leukemia Research

Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma

Open access
Walker, Brian A., Wardell, Christopher P., Chiecchio, Laura, Smith, Emma M., Boyd, Kevin D., Neri, Antonino, Davies, Faith E., Ross, Fiona M. +1 more·2011·Blood

Abstract

We used genome-wide methylation microarrays to analyze differences in CpG methylation patterns in cells relevant to the pathogenesis of myeloma plasma cells (B cells, normal plasma cells, monoclonal gammopathy of undetermined significance [MGUS], presentation myeloma, and plasma cell leukemia). We show that methylation patterns in these cell types are capable of distinguishing nonmalignant from malignant cells and the main reason for this difference is hypomethylation of the genome at the transition from MGUS to presentation myeloma. In addition, gene-specific hypermethylation was evident at the myeloma stage. Differential methylation was also evident at the transition from myeloma to plasma cell leukemia with remethylation of the genome, particularly of genes involved in cell–cell signaling and cell adhesion, which may contribute to independence from the bone marrow microenvironment. There was a high degree of methylation variability within presentation myeloma samples, which was associated with cytogenetic differences between samples. More specifically, we found methylation subgroups were defined by translocations and hyperdiploidy, with t(4;14) myeloma having the greatest impact on DNA methylation. Two groups of hyperdiploid samples were identified, on the basis of unsupervised clustering, which had an impact on overall survival. Overall, DNA methylation changes significantly during disease progression and between cytogenetic subgroups.

Integrity signals

Registry

Crossref · 10.1182/blood-2010-04-279539

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Walker, B. A., Wardell, C. P., Chiecchio, L., Smith, E. M., Boyd, K. D., Neri, A., Davies, F. E., Ross, F. M., & Morgan, G. J.
Affiliations
  • Institute of Cancer Research (GB)
  • Wessex Regional Genetics Laboratory (GB)
  • University of Milan (IT)
Venue
Blood
Published
2011-01-13
Volume
117
Issue
2
Pages
553-562
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2127009065
Cited by
267
References
1
Citations by year
2026: 3 · 2025: 15 · 2024: 8 · 2023: 13 · 2022: 16 · 2021: 21 · 2020: 19 · 2019: 15 · 2018: 23 · 2017: 14 · 2016: 17 · 2015: 21 · 2014: 20 · 2013: 24 · 2012: 21
FWCI
12.22
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
  • ePrints Soton (University of Southampton) (submittedVersion)
Funders
  • Cancer Research UK
  • National Institute for Health and Care Research
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords
multiple myeloma, DNA methylation, CpG methylation, plasma cells, monoclonal gammopathy of undetermined significance, plasma cell leukemia, hypomethylation, hyperdiploidy, cytogenetics, disease progression, prognosis, overall survival, cell adhesion genes
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Dexamethasone, Doxorubicin, Humans, Melphalan, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Prednisolone, Prognosis, Thalidomide, Vincristine, Cluster Analysis, In Situ Hybridization, Fluorescence, Disease Progression, DNA Methylation, Stem Cell Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review